This article is more than 5 years old. Information may no longer be current.

CORDLESS trial: More than half of patients did not have recurrence of symptoms of Dupuytren’s contracture

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

More than half of patients who received collagenase clostridium histolyticum did not show recurrent symptoms of Dupuytren’s contracture, according to a study presented at the American Society for Surgery of the Hand Annual Meeting.

In the Collagenase Optimal Reduction of Dupuytren’s - Long-term Evaluation of Success Study (CORDLESS) trial, Clayton A. Peimer, MD, clinical professor of Surgery at Michigan State University Medical School and Marquette General Healthcare, and colleagues followed 539 patients as they completed a 4-year follow-up after receiving Xiaflex (Auxilium Pharmaceuticals; Horsham, Penn.), a collagenase clostridium histolyticum (CCH) injection. The study analyzed patients starting from 2 years after the first injection with a minimum of 6 months between visits. They determined clinical success as a 0° to 5° correction and a recurrence as surgical intervention or a 20° or more increase with a palpable cord, according to the abstract.

Overall, they found that 57.9% of patients who received CCH did not have a recurrence of symptoms. The increase in recurrence slowed from 7.1% between years 3 and 4 of the trial compared with 15.4% between years 2 and 3. Patients with CCH injections had a higher recurrence of symptoms in the proximal interphalangeal joints than metacarpophalangeal joints. The researchers also found that 87.2% of patients did not need surgical intervention as of the 4-year follow-up.

“These data represent an important piece of information physicians, patients and payers can consider when determining the most appropriate treatment option for their patients,” Peimer stated in a press release.

Reference:

Hotchkiss RN. Paper #79. Presented at: American Society for Surgery of the Hand Annual Meeting. Oct. 3-5, 2013; San Francisco.

Disclosures: Hotchkiss, Peimer and Coleman receive research support from Auxilium Pharmaceuticals Inc. Peimer is a paid consultant for Auxilium Pharmaceuticals Inc. Coleman receives stock options from Auxilium Pharmaceuticals Inc. Coleman, Smith, Tursi and Kaufman receive other financial support from Auxilium Pharmaceuticals Inc.